Sep 19, 2018
MediSieve as a 1st Runner Up at Xcelerate Startup Pitch Competition
MediSieve wins 1st runner up at prestigious Boston Biotech Week start up competition
LONDON – September 19, 2018 – Medical device company, MediSieve, received accolades for their ground breaking work during the Biotech Week held in Boston in September 2018. MediSieve won first runner up for Best Business Plan at the Xcelerate Startup Pitch Competition hosted by Xcelerate Insight and EBD Group. The pitch competition is designed to give early stage companies exposure to possible investors and partners. It is judged by top venture capitalists and industry experts.
MediSieve is a medical device company whose magnetic blood filtration system has the ability to specifically and selectively remove disease-causing agents from the blood. The technology has the potential to transform the treatment of blood borne diseases such as sepsis, leukaemia and malaria.
George Frodsham, CEO at MediSieve explained that "Our pioneering technology involves targeting specific components that cause the diseases and removing them from the patient’s bloodstream. This provides clinicians with a tool to target and remove infected cells, pathogens, toxins, cytokines and others. We are delighted to have received the first runner up award at the Xcelerate Startup Pitch Competition as we were up against many other excellent entrepreneurs in the field of life science." George explains how he started the company and the amazing potential of their technology in this interview.
Along with 16 other entrepreneurs, MediSieve presented at the Xcelerate Startup Pitch competition at BioPharm America earlier this month. All the entrepreneurs presented major undertakings which will have a major impact in life science. Each start up presented their business, with visuals, to an audience which included a panel of investor judges.
Only five of the startups in attendance received an award, with RubrYcs Therapeutic winning the competition.
On the judging panel were: Cheryl Cui of Nest.Bio Ventures, Janelle Anderson of Versant Ventures, Christine Brennan of MRL Ventures Fund, Matthew Hammond of RA Capital Management, Stefan Vitorovic of Vida Ventures, and Paulina Hill of Polaris Partners.
The first runners up were: for best pitch, VisikolInc and for best business plan, MediSieve Limited. The second runners up were: for best pitch, Envisagenics and for best business plan, Cairn Biosciences.
About Magnetic Blood Filtration
MediSieve's Magnetic Blood Filtration Platform is intended to enable the rapid and specific depletion of specific agents from the bloodstream of patients. The extracorporeal therapy uses therapeutic Magnetic Beads that are designed to bind specifically to the clinical target. The Beads are introduced into the extracorporeal circuit during the therapy, mixing with the patient’s blood and binding to the clinical targets. The Delivery Platform captures all the Magnetic Beads and bound targets, preventing their return to the patient.
About MediSieve
MediSieve is a London-based BioTech start-up that has developed Magnetic Blood Filtration, a revolutionary platform therapy that enables the physical removal of specific substances from the bloodstream of patients. It can be used (1) as a direct treatment, (2) to increase the safety and efficacy of other therapies, or (3) to enable personalised medicine. The company is a spin-off from University College London and is developing its products at the White City Innovation District in West London. MediSieve is actively seeking investment and partnerships.
MEDIA CONTACT:
Alina Kagermazova
INVESTOR AND PARTNERSHIP CONTACT:
George Frodsham
